Slide 1: Welcome Investors June 2025
Welcome Investors March 2022 Welcome Investors June 2025
Slide 2: Forward Looking Statements
Forward Looking Statements 2 Some of the statements contained in this Report are forward - looking statements within the meaning of Section 27A of the Securiti es Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Management and representati
Slide 3: Who We Are
Who We Are UFP Technologies is a contract development and manufacturing organization (CDMO) that specializes in single use polymer based, medical devices 3 Ticker: UFPT Headquarters: Newburyport, MA Annual Revenue: ~$ 600 million 1 ~4,000 + Associates/ Temps Established: 1963 20 Manufacturing Facili
Slide 4: Helping customers get medical devices to market
We help our customers get their medical devices to market by offering expertise in design, materials, and global manufacturing locations 4 Design & engineering capabilities Materials expertise Strategic locations Precision manufacturing Shaping Innovation
Slide 5: Our Process
Our Process Innovative process from design and engineering to manufacturing and delivery 5
Slide 6: Product Development Business
Product Development Business 6 We bring deep experience in flexible material - based device manufacturing, from components and packaging, to final device assembly High Margin Added Expertise Stronger Customer Relationships Long Term Manufacturing 1 2 3 4 BENEFITS
Slide 7: MedTech Portfolio
MedTech Portfolio Robotic Drapes Revascularization Device Needleless Injection Port Cleaner MedSurg Bed Negative Pressure Wound Therapy Patient Safety 7
Slide 8: Global Medical Device Market and Customers
$518 billion, 6.3% CAGR 1 Global Medical Device Market Customers include 26 of the top 30 largest medical device manufacturers in the world 2 1. Fortune Business Insights - $518 billion as of 2023. 6.3% CAGR for a forecast period of 2024 - 2032. 2. Medical Design & Outsourcing 2024 MedTech Big 100.
Slide 9: Medical Segment Overview
Medical Segment Overview $518 Billion Global Device Market, 6.3% CAGR 1 Therapeutic Area % of Sales 2 1 Fortune Business Insights - $518 billion as of 2023. 6.3% CAGR for a forecast period of 2024 - 2032. 2 Annual mix of revenue through April, 2025 Market Growth High Teens 26% Robotic Surgery LDD 25
Slide 10: Surrounding a High-Growth End Market: Robotic Surgery
Surrounding a High - Growth End Market: Robotic Surgery 1 Surgical Robotics Market: Growth, Size, Share, and Trends Markets and MarketsTM August 2024 2 NIH 310 Million major surgeries performed each year: Geoffrey P Dobson 3 Towards Healthcare: Robotic Surgery Market Sizing • Market Size : ~$11B (20
Slide 11: Growth Strategy
Growth Strategy 11 Internal Growth: Market To Our Sweet Spot Strategic Acquisitions TWO - PRONGED
Slide 12: Organic Growth Opportunity
12 Organic Growth Opportunity Focus on high growth niche segments (MedTech – approximately 91% of revenue and growing) » Single - use, single - patient » Customer funded development Market to our sweet spot and differentiated capabilities » Leverage technology differentiation » Engineering resources
Slide 13: Acquisition Growth Opportunity
13 Acquisition Growth Opportunity Continue to Focus on Higher - Growth, Higher - Margin MedTech Opportunities that Create Value » Become more valuable to our customers » Strategic focus – new capability, geography, growing market segment, materials » Add scale » Look for synergistic opportunities »
Slide 14: M&A Strategy Centered Upon Enhanced Capabilities
M&A Strategy Centered Upon Providing Enhanced Capabilities Based On Our Customer Needs • Customer demand driven approach • 7 acquisitions since 2021 • Target niche, critical technologies in growing end markets • Product orientation to single use, low - ASP, high cost of failure • Focus on only custo
Slide 15: MedTech Sales over time
0 100,000,000 200,000,000 300,000,000 400,000,000 500,000,000 600,000,000 2021 2022 2023 2024 MedTech Sales over time Medical Sales UFP Annual Sales $451 million MedTech Proven Acquisition Integration Model Executing Strategy for performance from diversified industrial to MedTech $132 million MedTec
Slide 16: Why Invest?
Why Invest? 16 Significant market growth opportunities Barriers to entry Strong customer relationships Experienced management team Proven growth strategy Attractive financial metrics
Slide 17: Significant Market Growth Opportunities
17 Significant Market Growth Opportunities Market Focused On » Better Patient Outcomes » Infection Prevention » Reducing Healthcare Costs Global Footprint » Bringing New Opportunities Focused on fast growing segments
Slide 18: Competitive Advantage
Competitive Advantage » Advanced systems (extensive quality certifications) » In addition to existing equipment, engineers will design product specific innovations in order to meet customer needs Quality & Regulatory » In - house custom equipment manufacturing capabilities Custom Equipment » Numerou
Slide 19: Proven Growth Strategy Creating Shareholder Value
Proven Growth Strategy 19 Creating Shareholder Value
Slide 20: Financial Targets
Financial Targets 20
Slide 21: Financial Targets
Financial Targets 21 3 to 5 Year Financial Targets 12 - 18% Revenue Growth 28 - 31% Gross Margin 17 - 20% Adjusted Operating Margin
Slide 22: 12% to 18% Targeted Revenue Growth
12% to 18% Targeted Revenue Growth Internal Growth + Acquisitions $0 $100 $200 $300 $400 $500 $600 2020 2021 2022 2023 2024 March 2025 TTM 22 Revenue TTM = 12 - month period ended March 31, 2025
Slide 23: Gross Margin Target – 28% to 31%
Gross Margin Target – 28% to 31% Operating Leverage from Mix Shift + Acquisition synergies + Efficiencies 23 Gross Profit Margin Target: 28 - 31% 24.9% 24.8% 25.5% 28.1% 29.1% 28.5% 18.0% 20.0% 22.0% 24.0% 26.0% 28.0% 30.0% 32.0% 2020 2021 2022 2023 2024 Q1 2025
Slide 24: Adjusted Operating Margin Target - 17% to 20%
Adjusted Operating Margin Target - 17% to 20% Operating leverage from mix shift + acquisition synergies + efficiencies 24 Adjusted* Operating Margin Target: 17 - 20% *See non - GAAP reconciliation on slide 32 10.3% 11.1% 13.8% 15.9% 18.3% 17.4% 0.0% 5.0% 10.0% 15.0% 20.0% 2020 2021 2022 2023 2024 Q1
Slide 25: UFP Historical Stock Performance
UFP Historical Stock Performance 20 Years 25 *Measured as the percent increase from June 06, 2005 through June 04, 2025 0% 2000% 4000% 6000% 8000% 10000% 12000% UFP Technologies (UFPT) Price % Change Russell 2000 (RUT) Price % Change S&P 500 (SPX) Price % Change 7497% 237% 398%
Slide 26: R. Jeffrey Bailly Chairman, CEO & President Newburyport, Massachusetts Ronald Lataille CFO, Sr. VP
R. Jeffrey Bailly Chairman, CEO & President Newburyport, Massachusetts Ronald Lataille CFO, Sr. VP & Treasurer Newburyport, Massachusetts UFP Technologies 100 Hale St. Newburyport, MA 01950 978 - 352 - 2200 investorinfo@ufpt.com www.ufpt.com
Slide 27: Reconciliation of Non-GAAP Results
Appendix Reconciliation of Non - GAAP Results 27 (in Millions) 2020 2021 2022 2023 2024 Q1 2025 Revenue, As Reported $ 179.4 $ 206.3 $ 354.0 $ 400.1 $ 504.4 $ 148.1 Operating Income, as Reported 16.7 21.2 55.4 55.7 80.9 23.1 Add: Purchase Accounting Expenses - - - - 1.1 - Add: Acquisition Related Co